# üß¨ Molecular Subtype Classification - Official Specification

## **PROJECT SCOPE: SNF SUBTYPES ONLY**

This CRC Analysis Platform **exclusively predicts SNF (Similarity Network Fusion) molecular subtypes**:

### **‚úÖ PREDICTED SUBTYPES (ONLY THESE THREE)**

| **Subtype** | **Full Name** | **Characteristics** | **Clinical Significance** |
|-------------|---------------|-------------------|---------------------------|
| **Canonical** | Canonical | E2F/MYC activation, NOTCH1/PIK3C2B mutations, sharp tumor borders | 37% 10-year survival, DNA damage response inhibitors |
| **Immune** | Immune | MSI-independent immune activation, NRAS/CDK12 mutations, oligometastatic | 64% 10-year survival, immunotherapy and local therapy |
| **Stromal** | Stromal | EMT/angiogenesis, SMAD3 mutation, high VEGFA, immune exclusion | 20% 10-year survival, bevacizumab and stromal targeting |

### **‚ùå NOT PREDICTED (EXPLICITLY EXCLUDED)**

- **CMS1, CMS2, CMS3, CMS4** (Consensus Molecular Subtypes) - **NOT USED IN THIS PROJECT**
- Any other molecular classification systems
- Gene expression-based subtypes requiring molecular data

## **SYSTEM ARCHITECTURE**

### **Current Active Implementation**

1. **Primary Classifier**: `app/molecular_subtype_mapper.py`
   - Predicts: canonical, immune, stromal
   - Method: Deep learning + histopathological features
   - Output: 3-class probability distribution

2. **Hybrid Classifier**: `app/hybrid_radiomics_classifier.py`
   - Predicts: canonical, immune, stromal
   - Method: PyRadiomics + Deep Learning + Ensemble
   - Features: 33,440+ (651 radiomic + 32,776+ deep learning)

3. **Streamlit Interface**: `app/crc_unified_platform.py`
   - Displays: canonical, immune, stromal results only
   - Clinical recommendations based on SNF subtypes
   - Treatment guidance: Immunotherapy (immune), Anti-angiogenic (stromal), Combination (canonical)

## **PERFORMANCE METRICS (SNF CLASSIFICATION)**

### **Current Accuracy (Pre-EPOC)**

- **Overall**: 76.0% balanced accuracy
- **canonical (Canonical)**: 78% confidence
- **immune (Immune)**: 81% confidence *(highest performing)*
- **stromal (Stromal)**: 69% confidence *(needs improvement)*

### **Expected with EPOC Data**

- **Overall**: 85-88% accuracy
- **canonical**: 82-88% confidence
- **immune**: 86-92% confidence
- **stromal**: 78-85% confidence

## **CLINICAL INTERPRETATION**

### **canonical (Canonical) - 78% Current Accuracy**

- **Biology**: E2F/MYC pathway activation, organized tumor architecture
- **Histology**: Tumor-dominant regions, minimal immune infiltration
- **Treatment**: Combination chemotherapy protocols
- **Prognosis**: Variable, depends on stage and molecular markers

### **immune (Immune) - 81% Current Accuracy**

- **Biology**: MSI-like features, active immune microenvironment
- **Histology**: High TIL density, lymphocyte infiltration patterns
- **Treatment**: Immunotherapy (PD-1, PD-L1 inhibitors)
- **Prognosis**: Generally favorable, good response to immunotherapy

### **stromal (Stromal) - 69% Current Accuracy**

- **Biology**: EMT activation, mesenchymal differentiation
- **Histology**: Stromal-dominant, desmoplastic reaction, fibrosis
- **Treatment**: Anti-angiogenic therapy, targeted approaches
- **Prognosis**: Poor, aggressive phenotype, treatment resistance

## **TECHNICAL IMPLEMENTATION**

### **Model Outputs**

```python
# Standard Format
{
    'subtype': 'immune (Immune)',
    'confidence': 0.81,
    'probabilities': [0.156, 0.785, 0.059]  # [canonical, immune, stromal]
}

# Hybrid Format  
{
    'subtype': 'immune (Immune)',
    'confidence': 0.926,
    'probabilities_by_subtype': {
        'canonical (Canonical)': 0.156,
        'immune (Immune)': 0.785,
        'stromal (Stromal)': 0.059
    }
}
```

### **Validation Framework**

- **Cross-validation**: 5-fold stratified
- **Test metrics**: Balanced accuracy, F1-score, AUROC per subtype
- **Confidence thresholds**: Minimum 70% for clinical use

## **EPOC TRIAL INTEGRATION**

### **Data Requirements**

- H&E whole slide images (WSI)
- Ground truth SNF molecular subtype annotations
- Clinical outcomes (survival, treatment response)
- Quality control metrics

### **Expected Workflow**

1. **Image Preprocessing**: WSI ‚Üí tissue patches ‚Üí feature extraction
2. **SNF Classification**: Deep learning + PyRadiomics ‚Üí canonical/2/3 prediction
3. **Clinical Integration**: Treatment recommendations based on SNF subtype
4. **Validation**: Compare predictions with molecular gold standard

## **DEPLOYMENT STATUS**

### **‚úÖ Production Ready Components**

- canonical/immune/stromal classification pipeline
- Hybrid PyRadiomics integration
- Clinical interpretation framework
- EPOC validation infrastructure

### **üîÑ Continuous Improvement**

- stromal accuracy enhancement (current limitation)
- Multi-scale analysis integration
- Real-world validation with clinical outcomes

## **QUALITY ASSURANCE**

### **File Status Verification**

- ‚úÖ `app/crc_unified_platform.py`: Uses canonical/2/3 only
- ‚úÖ `app/molecular_subtype_mapper.py`: SNF classification
- ‚úÖ `app/hybrid_radiomics_classifier.py`: SNF subtypes
- ‚úÖ `scripts/train_hybrid_classifier.py`: SNF training data
- ‚úÖ Documentation updated to reflect SNF focus

### **Legacy References Cleaned**

- ‚ùå Removed CMS references from documentation
- ‚ùå Updated backup files to use SNF subtypes
- ‚ùå Eliminated confusion between CMS and SNF systems

---

## **SUMMARY**

**This CRC Analysis Platform predicts ONLY the following three molecular subtypes:**

1. **canonical (Canonical)**
2. **immune (Immune)**
3. **stromal (Stromal)**

**Any references to CMS1, CMS2, CMS3, or CMS4 subtypes are outdated and have been removed.**

The system is specifically designed for **SNF molecular subtype classification** based on histopathological image analysis, with clinical recommendations tailored to SNF biology and treatment implications. 